Product Data Sheet

Product Name: PF-07104091
Cat. No.: GC62660

Chemical Properties

Cas. No.	2460249-19-6		
Formula	$C_{19}H_{28}N_6O_4$	M.Wt	404.46
Solubility		Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	PF-07104091		

Protocol

Cell experiment [1]:

Cell lines

Preparation Method	1000 cell/well were seeded in 384-well plate in 20 μL of RPMI 1640, or DMEM, respectively in 10% FBS at 37 °C, 5%CO2. Assay-ready plates containing 1:3 serial dilutions of compounds in 100% DMSO were prepared using acoustic dispensing technology (ECHO), final starting concentration was 20 μM. Compound-treated plates were incubated for 4 days (2 doubling times) and cell proliferation estimated using PI staining.
Reaction Conditions	0-20μM for 4 days

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Applications	PF-07104091 inhibited T47D and KPL1 cells with IC50s of 0.785 and 0.603 μM, respectively.

Animal experiment [2]:

Animal models

Preparation Method

Dosage form

Applications

References:

[1]: Gharbi S I, Pelletier L A, Espada A, et al. Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy[J]. npj Breast Cancer, 2022, 8(1): 126.

Background

PF-07104091 is a CDK2/cyclin E1 inhibitor, a selective ATP-site inhibitor targeting the cyclin-bound activated state of the kinase [1]. PF-07104091(Example 13) inhibited CDK2/cyclin E1, GSK3β, CDK1/cyclin A2, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9, with Kis of 1.16, 537.81, 110, 238, 465 and 117 nM, respectively. PF-07104091 has anti-

tumor activity for cyclin E1-amplified cancers. [1].

PF-07104091 inhibited T47D and KPL1 cells with IC50s of 0.785 and 0.603 μM, respectively [2].

The combination of abemaciclib and PF-07104091decreased T47D and KPL1 cells survival compared to either single agent [2].

References:
[1]. Behenna, D. C.; Freeman-Cook, K. D.; Hoffman, R. L.; Nagata, A.; Ninkovic, S.; Sutton, S. C. Preparation of aminopyrazolylcyclopentyl carbamate derivatives for use as CDK2 inhibitors. WO 2020157652, 2020.
[2]. Gharbi S I, Pelletier L A, Espada A, et al. Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy[J]. npj Breast Cancer, 2022, 8(1): 126.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA